Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul-Sep;106(3):368504231182834.
doi: 10.1177/00368504231182834.

Fibrin Sealant TISSEEL Lyo as a haemostatic agent in vascular surgery: Results of randomized, controlled, patient-blinded, multicentre clinical study in the Russian population

Andrey A Karpenko  1 , Alexey V Cheban  1 , Artem A Rabtsun  1 , German Y Sokurenko  2 , Konstantin A Andreychuk  2 , Igor N Kim  3 , Valentin A Volf  3 , Maksim R Kuznetsov  4   5 , Igor I Prostov  6 , Natalia G Sapronova  6 , Nina D Mzhavanadze  7 , Alexey A Kamaev  7 , Igor A Suchkov  7
Affiliations
Randomized Controlled Trial

Fibrin Sealant TISSEEL Lyo as a haemostatic agent in vascular surgery: Results of randomized, controlled, patient-blinded, multicentre clinical study in the Russian population

Andrey A Karpenko et al. Sci Prog. 2023 Jul-Sep.

Abstract

Background: This phase III, controlled, patient-blinded, multicentre study in two parallel, equal-sized treatment groups compared the efficacy and safety of TISSEEL Lyo, fibrin sealant versus Manual Compression (MC) with surgical gauze pads for use as a haemostatic agent in patients who underwent vascular surgery in Russia.

Methods: Adult patients, both genders, who received peripheral vascular expanded polytetrafluoroethylene conduits and had suture line bleeding after surgical haemostasis were enrolled. Patients were randomized to be treated with TISSEEL Lyo or MC. The bleeding needed additional treatment and had to be assessed as grade 1 or 2 bleeding according to the Validated Intraoperative Bleeding scale. The primary efficacy endpoint was the proportion of patients achieving haemostasis at 4 min after treatment application (T4) at the study suture line, which was maintained until the closure of the surgical wound. The secondary efficacy endpoints included the proportion of patients achieving haemostasis at 6 min (T6) and 10 min (T10) after treatment application at the study suture line, which was maintained until closure of the surgical wound, as well as the proportion of patients with intraoperative and postoperative rebleeding. Safety outcomes included incidence of adverse events (AEs), surgical site infections and graft occlusions.

Results: A total of 110 patients were screened; 104 patients were randomized: (TISSEEL Lyo: 51 [49%] patients; MC: 53 [51%] patients). T4 haemostasis was achieved in 43 (84.3%) patients in the TISSEEL Lyo group and in 11 (20.8%) patients in the MC group (p < 0.001). Significantly more patients in TISSEEL Lyo group achieved the haemostasis at T6 (relative risk (RR) of achieving haemostasis 1.74 [95% confidence interval (CI) 1.37; 2.35]) and T10 (RR 1.18 [95% CI 1.05; 1.38]) versus MC. No one had intraoperative rebleeding. Postoperative rebleeding was reported only in one patient in the MC group. No treatment-emergent serious AEs (TESAEs) related to TISSEEL Lyo/MC, TESAEs leading to withdrawal and TESAEs leading to death were reported in patients during the study.

Conclusions: Data demonstrated TISSEEL Lyo had clinically and statistically significant superiority to MC as a haemostatic agent in vascular surgery at all measured time points including 4, 6 and 10 min and had proven to be safe.

Keywords: Fibrin sealant; TISSEEL Lyo; surgery; thrombin.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Patient disposition flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Spotnitz WD. Fibrin sealant: the only approved hemostat, sealant, and adhesive – a laboratory and clinical perspective. ISRN Surg 2014; 2014: 203943. - PMC - PubMed
    1. Hickman DA, Pawlowski CL, Sekhon UDS, et al.Biomaterials and advanced technologies for hemostatic management of bleeding. Adv Mater 2018; 30: 1700859. Epub 2017 Nov 22. PMID: 29164804; PMCID: PMC5831165. DOI: 10.1002/adma.201700859. - DOI - PMC - PubMed
    1. Chiara O, Cimbanassi S, Bellanova G, et al.A systematic review on the use of topical hemostats in trauma and emergency surgery. BMC Surg 2018; 18: 68. PMID: 30157821; PMCID: PMC6116382. - PMC - PubMed
    1. Edwards SJ, Crawford F, van Velthoven MH, et al.The use of fibrin sealant during non-emergency surgery: a systematic review of evidence of benefits and harms. Health Technol Assess 2016; 20: 1–224. - PMC - PubMed
    1. Kjaergard HK, Fairbrother JE. Controlled clinical studies of fibrin sealant in cardiothoracic surgery – a review. Eur J Cardiothorac Surg 1996; 10: 727–733. - PubMed

Publication types